Current Management of Angiosarcoma: Recent Advances and Lessons From the Past

被引:32
作者
Florou, Vaia [1 ]
Wilky, Breelyn A. [2 ]
机构
[1] Univ Utah, Sch Med, Dept Internal Med, Div Oncol,Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA
[2] Univ Colorado, Div Med Oncol, Sch Med, Dept Med, 1665 Aurora Court Anschutz Canc Pavil, Aurora, CO USA
关键词
Angiosarcoma; Angiosarcoma Project; Immunotherapy; EORTC SOFT-TISSUE; PHASE-II TRIAL; PAZOPANIB P; RARE CANCER; OPEN-LABEL; PACLITAXEL; THERAPY; MULTICENTER; REGORAFENIB; BEVACIZUMAB;
D O I
10.1007/s11864-021-00858-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion statement Despite their rarity, angiosarcomas are one of the most aggressive soft tissue sarcomas. Management can often be challenging due to their location and infiltrative nature. A multidisciplinary treatment approach is always warranted, but the recurrence remains high even for localized tumors despite multimodality treatment. In the metastatic setting, cytotoxic chemotherapies, targeted therapies, and, more recently, immunotherapy are used. The sequence of systemic therapies remains currently a topic of active investigation. Over the last couple of years, there have been significant advances in understanding angiosarcoma biology, most notably via patient-driven initiatives like the Angiosarcoma Project. The knowledge derived from such translational work has led to identifying potential biomarkers of response to treatments and exploring new therapeutic avenues. More clinical trials are underway to expand treatment options and improve patient outcomes.
引用
收藏
页数:10
相关论文
共 46 条
[1]   An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas† [J].
Agulnik, M. ;
Yarber, J. L. ;
Okuno, S. H. ;
von Mehren, M. ;
Jovanovic, B. D. ;
Brockstein, B. E. ;
Evens, A. M. ;
Benjamin, R. S. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :257-263
[2]  
Agulnik M, 2020, J CLIN ONCOL, V38
[3]   Malignant vascular tumors-an update [J].
Antonescu, Cristina .
MODERN PATHOLOGY, 2014, 27 :S30-S38
[4]   Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing [J].
Boichard, Amelie ;
Wagner, Michael J. ;
Kurzrock, Razelle .
GENOME MEDICINE, 2020, 12 (01)
[5]   Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma [J].
Chan, Jason Yongsheng ;
Lim, Jing Quan ;
Yeong, Joe ;
Ravi, Vinod ;
Guan, Peiyong ;
Boot, Arnoud ;
Tay, Timothy Kwang Yong ;
Selvarajan, Sathiyamoorthy ;
Nasir, Nur Diyana ;
Loh, Jie Hua ;
Ong, Choon Kiat ;
Huang, Dachuan ;
Tan, Jing ;
Li, Zhimei ;
Ng, Cedric Chuan-Young ;
Thuan Tong Tan ;
Masuzawa, Mikio ;
Sung, Ken Wing-Kin ;
Farid, Mohamad ;
Quek, Richard Hong Hui ;
Tan, Ngian Chye ;
Teo, Melissa Ching Ching ;
Rozen, Steven George ;
Tan, Patrick ;
Futreal, Andrew ;
Teh, Bin Tean ;
Soo, Khee Chee .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (11) :5833-5846
[6]   Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy - A Systematic Review [J].
Co, M. ;
Lee, A. ;
Kwong, A. .
CLINICAL ONCOLOGY, 2019, 31 (04) :225-231
[7]   Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study [J].
Constantinidou, Anastasia ;
Sauve, Nicolas ;
Stacchiotti, Silvia ;
Blay, Jean-Yves ;
Vincenzi, Bruno ;
Grignani, Giovanni ;
Rutkowski, Piotr ;
Guida, Michele ;
Hindi, Nadia ;
Klein, Alexander ;
Thibaud, Valentin ;
Sufliarsky, Jozef ;
Desar, Ingrid ;
Steeghs, Neeltje ;
Litiere, Saskia ;
Gelderblom, Hans ;
Jones, Robin L. .
ESMO OPEN, 2020, 5 (04)
[8]   Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma [J].
D'Angelo, Sandra P. ;
Munhoz, Rodrigo R. ;
Kuk, Deborah ;
Landa, Johnathan ;
Hartley, Eliza W. ;
Bonafede, Michael ;
Dickson, Mark A. ;
Gounder, Mrinal ;
Keohan, Mary L. ;
Crago, Aimee M. ;
Antonescu, Cristina R. ;
Tap, William D. .
ONCOLOGY, 2015, 89 (04) :205-214
[9]  
Dickson Mark A., 2015, Sarcoma, V2015, P532478, DOI 10.1155/2015/532478
[10]  
Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO